Pfizer may outsource manufacturing some of its drugs to make way for coronavirus vaccine

Pfizer plans to outsource production of some of its drug portfolio to make way for a rapidly growing vaccine manufacturing effort, the company said Monday.

The drugmaker will lean on its 200-strong network of contractors as part of a plan to “build a robust U.S.-based supply chain as well as one based in Europe,” a Pfizer spokesperson said.

Pfizer has dedicated enormous resources to churning out hundreds of millions of doses of a possible coronavirus vaccine.

The drugmaker will lean on its 200-strong network of contractors as part of a plan to “build a robust U.S.-based supply chain as well as one based in Europe,” a Pfizer spokesperson said.